secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001140361-26-006116
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed reports FY2025 revenue $606M (+67% YoY); guides BRINSUPRI to at least $1B in FY2026
--------------------------------------------------------------------------------

- Full-year 2025 total revenues $606.4M (+67% YoY); ARIKAYCE $433.8M (+19%), BRINSUPRI $172.7M since Aug launch.
- Guides FY2026 BRINSUPRI revenue ≥$1B, ARIKAYCE $450-470M; net loss $1,276.8M ($6.42/share) vs $913.8M in 2024.
- Cash & equivalents ~$1.4B; plans to fund pipeline including ENCORE, CEDAR, TPIP Phase 3, and gene therapy programs.
- Director David W.J. McGirr will not stand for re-election at 2026 annual meeting, no disagreement with company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/0001140361-26-006116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/ef20066055_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-006116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer